Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 30

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 Street LLC, the representative of the underwriters in the Initial Public Offering,
200,000 ordinary shares (the “representative shares”) at the time of the consummation of Initial Public Offering and 30,000
representative shares at the closing of the over-allotment option. The holders of the representative shares have agreed (i) that they
will not transfer, assign or sell any such shares without our prior consent until the completion of the initial Business Combination,
(ii) to waive their redemption rights (or right to participate in any tender offer) with respect to such shares in connection with the
completion of the initial Business Combination and (iii) to waive their rights to liquidating distributions from the Trust Account with
respect to such shares if the Company fails to complete its initial Business Combination within 15 months from the closing of the Initial
Public Offering (or up to 21 months from the closing if the Company extends the period of time to consummate a Business Combination).

The
representative shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately
following the commencement of sales of the Initial Public Offering pursuant to Rule 5110(e)(1) of FINRA’s NASD Conduct Rules. Pursuant
to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that
would result in the economic disposition of the securities by any person for a period of 180 days immediately following the commencement
of sales of the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days
immediately following the commencement of sales of the Initial Public Offering except to any underwriter and selected dealer participating
in the Initial Public Offering and their bona fide officers or partners.

Subscription
Receivable — On January 29, 2025, the Company issued a new unsecured subscription promissory note to the Sponsor in
connection with the amended and restated units purchase agreement (as described in Note 5) pursuant to which the Company may borrow
up to an aggregate principal amount of $1,100,000 working capital loans. The Sponsor further agrees that such loans shall be
converted into Private Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the
Sponsor acknowledges and agrees that